CAS
NVCR icon

Coppell Advisory Solutions’s NovoCure NVCR Stock Holding History

Coppell Advisory Solutions’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Buy
+38,953
New +$589K 0.4% 50
2025
Q1 		– Sell
-76
Closed -$2.29K – 1343
2024
Q4 		$2.29K Sell
76
-1,048
-93% -$22.2K ﹤0.01% 1512
2024
Q3 		$17.5K Buy
1,124
+214
+24% +$3.88K ﹤0.01% 917
2024
Q2 		$15.6K Buy
+910
New +$16K ﹤0.01% 873

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Coppell Advisory Solutions's NVCR Position: Q2 2026 in Review

Coppell Advisory Solutions opened a new position in NovoCure (NVCR) in Q2 2026: 38,953 shares worth $4.86M. The stake represents 0.4% of the portfolio and ranks #50 among its holdings. This is a return to the name: Coppell Advisory Solutions previously reported a position in NVCR as recently as Q4 2024.

Coppell Advisory Solutions first reported a position in NVCR in Q2 2024 and has held it in 4 quarters since. 217 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Coppell Advisory Solutions held 38,953 shares of NovoCure worth $4.86M as of Q2 2026.
  • NovoCure was a new Coppell Advisory Solutions position in Q2 2026.
  • NovoCure made up 0.4% of Coppell Advisory Solutions's portfolio in Q2 2026, its #50 holding.
  • Coppell Advisory Solutions first reported a position in NovoCure in Q2 2024 and has held it in 4 quarters since.
  • 217 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.